Liver Iron Loading in Alcohol-Associated Liver Disease
Overview
Authors
Affiliations
Alcohol-associated liver disease (ALD) is a common chronic liver disease with increasing incidence worldwide. Alcoholic liver steatosis/steatohepatitis can progress to liver fibrosis/cirrhosis, which can cause predisposition to hepatocellular carcinoma. ALD diagnosis and management are confounded by several challenges. Iron loading is a feature of ALD which can exacerbate alcohol-induced liver injury and promote ALD pathologic progression. Knowledge of the mechanisms that mediate liver iron loading can help identify cellular/molecular targets and thereby aid in designing adjunct diagnostic, prognostic, and therapeutic approaches for ALD. Herein, the cellular mechanisms underlying alcohol-induced liver iron loading are reviewed and how excess iron in patients with ALD can promote liver fibrosis and aggravate disease pathology is discussed. Alcohol-induced increase in hepatic transferrin receptor-1 expression and up-regulation of high iron protein in Kupffer cells (proposed) facilitate iron deposition and retention in the liver. Iron is loaded in both parenchymal and nonparenchymal liver cells. Iron-loaded liver can promote ferroptosis and thereby contribute to ALD pathology. Iron and alcohol can independently elevate oxidative stress. Therefore, a combination of excess iron and alcohol amplifies oxidative stress and accelerates liver injury. Excess iron-stimulated hepatocytes directly or indirectly (through Kupffer cell activation) activate the hepatic stellate cells via secretion of proinflammatory and profibrotic factors. Persistently activated hepatic stellate cells promote liver fibrosis, and thereby facilitate ALD progression.
Mechanism and application prospect of ferroptosis inhibitors in improving osteoporosis.
Wang J, Chen T, Gao F Front Endocrinol (Lausanne). 2024; 15:1492610.
PMID: 39735645 PMC: 11671246. DOI: 10.3389/fendo.2024.1492610.
Zahng Y, Lan J, Ma X, Zhou Q, Qin M, Gao L Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(12):2265-2275.
PMID: 39725614 PMC: 11683359. DOI: 10.12122/j.issn.1673-4254.2024.12.01.
Iron chelation as a new therapeutic approach to prevent senescence and liver fibrosis progression.
Amengual J, Alay A, Vaquero J, Gonzalez-Sanchez E, Bertran E, Sanchez A Cell Death Dis. 2024; 15(9):680.
PMID: 39289337 PMC: 11408630. DOI: 10.1038/s41419-024-07063-0.
Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives.
Yan M, Man S, Ma L, Guo L, Huang L, Gao W Clin Mol Hepatol. 2024; 30(4):620-648.
PMID: 38988278 PMC: 11540396. DOI: 10.3350/cmh.2024.0315.
Zheng Y, Zheng Y, Wang J, Zhao T, Wang L, Liang T World J Hepatol. 2024; 16(4):494-505.
PMID: 38689744 PMC: 11056900. DOI: 10.4254/wjh.v16.i4.494.